Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders
GUANGZHOU, China, Jan. 14, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd. today announced the publication of the Phase I clinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20 monoclonal antibody